Telehealth Intake Red Flags: What the Secret Shopper Study Taught Us to Watch For
The July 2026 Yale secret shopper study gave a name to a problem patients have long suspected: a lot of telehealth GLP-1 intake is thinner than it looks. Here's the specific list of red flags the study's methodology surfaced, so you know what to watch for on your own next evaluation.
What the study's methodology exposed
Researchers posing as patients found meaningful variation in how thoroughly platforms reviewed intake before prescribing — some approved essentially automatically off a questionnaire, with limited evidence of individualized clinical judgment being applied.
Red flags worth watching for
- Approval before you've finished describing your medical history. A genuine review takes at least some processing time after you submit.
- No mention of contraindication screening (personal or family history of medullary thyroid cancer, MEN 2 syndrome, pancreatitis) — these are standard questions for this drug class, and their absence is notable.
- No follow-up scheduling mentioned anywhere in the process, suggesting the relationship ends the moment medication ships.
- Marketing language that promises approval before any clinical review has happened ("you'll qualify," "guaranteed approval").
- No named, licensed clinician associated with your review — a legitimate provider can tell you who's reviewing your case, at least by credential if not by name.
What a solid intake process looks like instead
Eden Health From $196
LegitScript certified with a documented direct intake process and follow-up built in, rather than a one-time transaction.
Visit Eden Health →Paid linkWhat to actually do with this list
Use it as a checklist during your next evaluation, whether it's your first visit or a refill with an existing provider. None of these red flags alone necessarily means a provider is unsafe — but a pattern of several together is worth taking seriously, and worth asking the provider directly about before you proceed.